Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24120390 | 0.91 | HDAC1 (0.37) | HDAC2HDAC1CNR1CNR2 | |
| SCHEMBL21361260 | 0.90 | CYP2D6 (0.45) | CYP2D6ALDH1A1TSHRCYP2C19HSD17B10 | |
| SCHEMBL21361303 | 0.90 | CYP2D6 (0.41) | HDAC2HDAC1CNR1CNR2CYP2D6 | |
| SCHEMBL21361267 | 0.88 | CCNT1 (0.39) | HDAC2HDAC1GRIN2BCYP2D6KDM1A | |
| SCHEMBL21361258 | 0.85 | HDAC2 (0.35) | HDAC2HDAC1CNR1CNR2CYP2D6 | |
| SCHEMBL21361273 | 0.85 | HDAC2 (0.37) | HDAC2HDAC1CNR1CNR2CYP2D6 | |
| SCHEMBL21361272 | 0.85 | ALDH1A1 (0.38) | HDAC2HDAC1CNR1CNR2ALDH1A1 | |
| SCHEMBL22859729 | 0.85 | HDAC2 (0.41) | HDAC2HDAC1CNR1CNR2CYP2D6 | |
| SCHEMBL21361274 | 0.85 | HDAC2 (0.34) | HDAC2HDAC1CNR1CNR2CYP2D6 | |
| SCHEMBL21361246 | 0.84 | CYP3A4 (0.47) | CYP2D6ALDH1A1TSHRCYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765445-B1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-01-07 | — | — | US | disclosed |
| WO-2019175117-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | CBR3, DDT, CBR1 | HDAC2 964/4885HDAC1 845/4885GRIN2B 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.